MIF Inhibitor for Autoimmune Diseases & Immuno-Oncology
INV-88 is a novel class of proprietary oral small molecule NMEs that have been discovered by Innovimmune scientists. This platform consists of several structurally-distinct lead scaffolds which inhibit human macrophage migration inhibitory factor [MIF], a cytokine which is critically implicated in the pathogenesis of several Autoimmune and Immunoinflammatory Diseases. The important discovery, by Innovimmune, of potential novel oral immunomodulatory drugs is a significant advancement in the development of future treatments for these disorders with high unmet medical needs due to the current lack of available oral-based therapies for patients suffering from these debilitating diseases. The unique MOA of targeting MIF has been target validated in preclinical animal disease models and its preclinical Proof of Concept established in Rheumatoid Arthritis, Multiple Sclerosis, Alzheimer’s Disease, Type 1 and Type 2 Diabetes, Obesity, Lupus, Asthma, Crohn’s Disease, and Ulcerative Colitis.
Disorders stemming from increased autoimmunity and chronic inflammation share similar clinicopathologic attributes to those found in the initiation and development of various types of cancer. Elevated levels of the proinflammatory cyotokine, MIF, have been detected in both solid and liquid malignancies such as cancers of the prostate, breast, colon, lung, and blood. Additionally, strong evidence has demonstrated that MIF overexpression is implicated in increased proliferation, angiogenesis, and metastasis in these cancers. Harnessing the long-established link between inflammation and cancer induction, Innovimmune’s INV-88 platform of compounds has been adapted to disable MIF-mediated tumorigenesis. In preclinical studies, conducted by Innovimmune’s Discovery team, INV-88 lead compounds ameliorated tumorigenic phenotypes by perturbing proinflammatory cytokine secretion and attenuating key pro-cancer signaling networks in multiple cell-based cancer models.
High priority INV-88 lead compound candidates have advanced to final Discovery stage, with several back-up scaffolds concurrently in development. The INV-88 lead candidates have been designed with highly favorable physico-chemical and ADMET properties that would translate into next-generation immunomodulatory therapies with a higher potency, better efficacy, superior safety profile and a wider therapeutic index providing better patient treatments.